TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37690061

Group type: EXPERIMENTAL
Intervention: Lorundrostat 100 mg once daily
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Lorundrostat 50 mg once daily
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Lorundrostat 12.5 mg once daily
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Lorundrostat 25 mg twice daily
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Lorundrostat 12.5 mg twice daily
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Lorundrostat 100 mg once daily (participants without suppressed PRA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Lorundrostat 50 mg once daily vs Placebo
Number of subjects: 200

Group type: COMPARATOR
Intervention: Lorundrostat 100 mg once daily vs Placebo
Number of subjects: 200
Study: 37690312

Group type: EXPERIMENTAL
Intervention: d-serine and auditory remediation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37690320

Group type: EXPERIMENTAL
Intervention: Ribociclib + ET
Number of subjects: 53

Group type: COMPARATOR
Intervention: ET only
Number of subjects: 53
Study: 37690438

Group type: EXPERIMENTAL
Intervention: Pedometer tracking
Number of subjects: 80
Study: 37690525

Group type: EXPERIMENTAL
Intervention: TAU + Therapeutic Education System-Native Version (TES-NAV)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: TAU + TES-NAV
Number of subjects: 53

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 53
Study: 37690669

Group type: EXPERIMENTAL
Intervention: Molnupiravir (800 mg twice daily for 5 days)
Number of subjects: 1527

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1527

Group type: EXPERIMENTAL
Intervention: Molnupiravir
Number of subjects: 1527
Study: 37690784

Group type: EXPERIMENTAL
Intervention: High-dose (40 mg/day)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Low-dose (20 mg/day)
Number of subjects: 86
Study: 37690874

Group type: EXPERIMENTAL
Intervention: CHIKV VLP vaccine in seropositive recipients
Number of subjects: 39

Group type: COMPARATOR
Intervention: CHIKV VLP vaccine in seronegative recipients
Number of subjects: 39
Study: 37690911

Group type: EXPERIMENTAL
Intervention: Double reading by one radiologist plus AI
Number of subjects: 55581

Group type: EXPERIMENTAL
Intervention: Single reading by AI
Number of subjects: 55581

Group type: EXPERIMENTAL
Intervention: Triple reading by two radiologists plus AI
Number of subjects: 55581

Group type: COMPARATOR
Intervention: Double reading by two radiologists
Number of subjects: 55581
Study: 37690946

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37690994

Group type: EXPERIMENTAL
Intervention: Genetic variant rs71630754 (additive model)
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Lower expression of ERAP1
Number of subjects: 907
Study: 37691028

Group type: EXPERIMENTAL
Intervention: Screening tools based on clinical parameters combined with immunological molecular markers
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Molecular variables alone
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: IL-1Ra, IL-17A, CCL19, CX3CL1, TNF
Number of subjects: 551

Group type: COMPARATOR
Intervention: Screening tools based on clinical parameters
Number of subjects: 551
Study: 37691092

Group type: EXPERIMENTAL
Intervention: App-based management system for chronic pain patients with SCS implants
Number of subjects: 82

Group type: COMPARATOR
Intervention: Monthly online follow-ups
Number of subjects: 82
Study: 37691144

Group type: EXPERIMENTAL
Intervention: Surgical treatment with connective tissue graft (CTG) and individualized supportive peri-implant care (SPC) program
Number of subjects: 16
Study: 37691321

Group type: EXPERIMENTAL
Intervention: Transition readiness knowledge
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Transition readiness behaviour
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Anxiety levels
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Health self-management and transition readiness perceptions
Number of subjects: 512
Study: 37691437

Group type: EXPERIMENTAL
Intervention: Worst Pruritus Numerical Rating Scale (NRS)
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Atopic Dermatitis Symptom Scale (ADerm-SS)
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Atopic Dermatitis Impact Scale (ADerm-IS)
Number of subjects: 882
Study: 37691474

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 37691530

Group type: EXPERIMENTAL
Intervention: Ofatumumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Teriflunomide
Number of subjects: 0
Study: 37691729

Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) 50 mg
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) 100 mg
Number of subjects: 1228

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) 100 mg (for nonresponders)
Number of subjects: 1228

Group type: COMPARATOR
Intervention: Placebo (PBO) (for responders to PBO induction)
Number of subjects: 1228
Study: 37691796

Group type: EXPERIMENTAL
Intervention: Attachment-based compassion therapy (ABCT)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Relaxation therapy (active control)
Number of subjects: 140
Study: 37691850

Group type: EXPERIMENTAL
Intervention: Menthol solution 0.01%
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo - noncaloric berry-flavored solution
Number of subjects: 13
Study: 37691865

Group type: EXPERIMENTAL
Intervention: Ramucirumab (RAM) plus Erlotinib (ERL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PL) plus Erlotinib (ERL)
Number of subjects: 0
Study: 37691871

Group type: EXPERIMENTAL
Intervention: Augmented reality navigation-guided localization
Number of subjects: 10
Study: 37691885

Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome, cisplatin and 5-fluorouracil (TPF)-based induction chemotherapy followed by de-escalated radiotherapy of 60 Gy with concurrent cisplatin
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome, cisplatin and 5-fluorouracil (TPF)-based induction chemotherapy followed by standard-dose radiotherapy of 70 Gy with concurrent cisplatin (for those with stable or progressive disease)
Number of subjects: 44
Study: 37692042

Group type: EXPERIMENTAL
Intervention: Postoperative infection (POI)
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Patients with POI
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Influence of POI on all-cause death
Number of subjects: 1460
Study: 37692126

Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg every 4 weeks for 52 weeks
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1059
Study: 37692969

Group type: EXPERIMENTAL
Intervention: High doses of nabiximols (up to 113.4 mg THC/105 mg CBD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 37693107

Group type: EXPERIMENTAL
Intervention: Cues of people smoking cigarettes (2000 ms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cues of cigarette paraphernalia (2000 ms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cues of people smoking cigarettes (2000 ms) for PLWHA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cues of people smoking cigarettes (1000 ms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cues of cigarette paraphernalia (1000 ms)
Number of subjects: 0
Study: 37693199

Group type: EXPERIMENTAL
Intervention: Left atrial late gadolinium enhancement (LA LGE)
Number of subjects: 1697
Study: 37693244

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 443
Study: 37693269

Group type: EXPERIMENTAL
Intervention: Retreatment with first-line anti-HCV drugs for 24 weeks with ribavirin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Retreatment with sofosbuvir/velpatasvir/ribavirin for 24 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Overall retreatment with first-line anti-HCV drugs
Number of subjects: 12
Study: 37693279

Group type: EXPERIMENTAL
Intervention: Early menarche
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: Onset of dysmenorrhea at menarche or several years after it
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: Physical symptoms accompanying menarche and menstrual period pain
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: Medical management of dysmenorrhea
Number of subjects: 1126
Study: 37693386

Group type: EXPERIMENTAL
Intervention: Genetic study of ARFID including saliva sample submission for genotyping.
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: ARFID-GEN study protocol.
Number of subjects: 3000
Study: 37693433

Group type: EXPERIMENTAL
Intervention: Pre-treatment functional connectivity of the seed with the cerebellum, insula, middle occipital gyrus, postcentral gyrus, and precuneus/superior parietal lobule.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Pre-treatment functional connectivity with the putamen.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Pre- to post-treatment changes in functional connectivity.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Pre-treatment functional connectivity between regions involved in attentional salience, self-generated thoughts, and external attention.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Behavioral and self-report measures of self-focused attention (SFA).
Number of subjects: 27
Study: 37693467

Group type: EXPERIMENTAL
Intervention: Robotic assisted bronchoscopy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electromagnetic navigational bronchoscopy
Number of subjects: 0
Study: 37693502

Group type: EXPERIMENTAL
Intervention: Subclass 1 (patients with septic shock)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Subclass 2 (patients with septic shock)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Noninfected controls without shock
Number of subjects: 98
Study: 37693586

Group type: EXPERIMENTAL
Intervention: Pre-treatment histidine concentration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-treatment concentrations of glutamate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-treatment concentrations of phenylalanine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-treatment concentrations of tyrosine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-treatment concentrations of valine
Number of subjects: 0
Study: 37693596

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 37693768

Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS (30 min) followed by occupational therapy (30 min) for 10 consecutive workdays
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sham rTMS (30 min) followed by occupational therapy (30 min) for 10 consecutive workdays
Number of subjects: 88
Study: 37693914

Group type: EXPERIMENTAL
Intervention: HSG4112
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37694347

Group type: EXPERIMENTAL
Intervention: T-DXd 5.4 mg/kg
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: T-DXd 6.4 mg/kg
Number of subjects: 152
Study: 37694399

Group type: EXPERIMENTAL
Intervention: Acoustic subcision at 100 Hz
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Acoustic subcision at 50 Hz
Number of subjects: 15
Study: 37694449

Group type: EXPERIMENTAL
Intervention: Garetosmab (10 mg/kg, intravenous, every 4 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (intravenous, every 4 weeks)
Number of subjects: 44
Study: 37694854

Group type: EXPERIMENTAL
Intervention: MNK inhibitor eFT508
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MNK inhibitors (eFT508, CGP57380, cercosporamide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: siRNA to deplete MNK
Number of subjects: 0
Study: 37695272

Group type: EXPERIMENTAL
Intervention: Telerehabilitation using the serious game 'MoveHero'
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-ASD individuals (control group)
Number of subjects: 22
Study: 37695331

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37695378

Group type: EXPERIMENTAL
Intervention: ixazomib plus lenalidomide and dexamethasone (IRd)
Number of subjects: 295
Study: 37695506

Group type: EXPERIMENTAL
Intervention: Upadacitinib (UPA)
Number of subjects: 296
Study: 37695585

Group type: EXPERIMENTAL
Intervention: SOC-tailored online intervention (chatbot delivering tailored health promotion messages via WhatsApp, 4 sessions every 2 weeks)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: SOC-tailored online intervention
Number of subjects: 396

Group type: COMPARATOR
Intervention: Standard non-SOC-tailored online intervention (chatbot delivering general SIV information via WhatsApp, 4 sessions every 2 weeks)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Standard non-SOC-tailored online intervention
Number of subjects: 396
Study: 37695586

Group type: EXPERIMENTAL
Intervention: GOC video intervention delivered by palliative care educators (PCEs) facilitating GOC conversations using video decision aids.
Number of subjects: 10802

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 10802

Group type: EXPERIMENTAL
Intervention: GOC video intervention for Black or African American individuals.
Number of subjects: 10802

Group type: EXPERIMENTAL
Intervention: GOC video intervention for Hispanic or Latino individuals.
Number of subjects: 10802

Group type: EXPERIMENTAL
Intervention: GOC video intervention for non-English speakers.
Number of subjects: 10802

Group type: EXPERIMENTAL
Intervention: GOC video intervention for people living with Alzheimer disease and related dementias.
Number of subjects: 10802
Study: 37695621

Group type: EXPERIMENTAL
Intervention: Opt-out automatic mammography referral
Number of subjects: 883

Group type: COMPARATOR
Intervention: Opt-in automated telephone call with option for mammography referral
Number of subjects: 883
Study: 37695623

Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382

Group type: COMPARATOR
Intervention: Ravulizumab vs Placebo
Number of subjects: 382
Study: 37695655

Group type: EXPERIMENTAL
Intervention: QTc Tracker app
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: QTc Tracker app with cardiologic on-call service
Number of subjects: 122

Group type: COMPARATOR
Intervention: Routine ECG workflow
Number of subjects: 122
Study: 37695657

Group type: EXPERIMENTAL
Intervention: Structured exercise group
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Exergame group (Nintendo Wii)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Serious game group (Becure Balance System)
Number of subjects: 69
Study: 37695740

Group type: EXPERIMENTAL
Intervention: Better orienting ability and more state rumination
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Better orienting efficiency and lower negative interpretation bias
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: State rumination
Number of subjects: 92
Study: 37695752

Group type: EXPERIMENTAL
Intervention: Research-grade device (Ax6)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Commercial device (DorsaVi ViMove2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-end multimodal system (DANU Sports System)
Number of subjects: 0
Study: 37695822

Group type: EXPERIMENTAL
Intervention: Virtual Reality Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study: 37695982

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37696264

Group type: EXPERIMENTAL
Intervention: delta-SIG ratio in rupture-destined aneurysms
Number of subjects: 65

Group type: COMPARATOR
Intervention: delta-SIG ratio in unruptured intracranial aneurysms
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: area under the receiver operating characteristic curve for delta-SIG ratio
Number of subjects: 65

Group type: COMPARATOR
Intervention: area under the receiver operating characteristic curve for size ratio
Number of subjects: 65
Study: 37696275

Group type: EXPERIMENTAL
Intervention: Avacincaptad pegol 2 mg
Number of subjects: 448

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 448
Study: 37696281

Group type: COMPARATOR
Intervention: Conventional fractionation (50 Gy in 25 fractions of 2 Gy)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Hypofractionation (40.05 Gy in 15 fractions of 2.67 Gy)
Number of subjects: 88
Study: 37696393

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept treatment
Number of subjects: 40
Study: 37696419

Group type: EXPERIMENTAL
Intervention: Selective shunt
Number of subjects: 98

Group type: COMPARATOR
Intervention: Non-shunt
Number of subjects: 98
Study: 37696565

Group type: EXPERIMENTAL
Intervention: Sotatercept
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37696588

Group type: EXPERIMENTAL
Intervention: Bimekizumab (BKZ) 160 mg every 4 weeks
Number of subjects: 702

Group type: COMPARATOR
Intervention: Adalimumab (ADA) 40 mg every 2 weeks
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Bimekizumab (BKZ) 160 mg every 4 weeks (after switch from PBO at Week 16)
Number of subjects: 702
Study: 37696589

Group type: EXPERIMENTAL
Intervention: Otilimab 90 mg
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Otilimab 150 mg
Number of subjects: 549

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Sarilumab
Number of subjects: 549
Study: 37696614

Group type: EXPERIMENTAL
Intervention: Pegozafermin 30 mg once weekly (q.w.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pegozafermin 44 mg every 2 weeks (q2w)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37696621

Group type: EXPERIMENTAL
Intervention: n-3 long-chain polyunsaturated fatty acids (LCPUFAs)
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: n-3 LCPUFA
Number of subjects: 736

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 736
Study: 37696629

Group type: EXPERIMENTAL
Intervention: 25 mg melatonin administered rectally via an enema daily for 28 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo administered rectally via an enema daily for 28 days
Number of subjects: 21
Study: 37696633

Group type: EXPERIMENTAL
Intervention: Active music listening
Number of subjects: 70

Group type: COMPARATOR
Intervention: Active audiobooks listening
Number of subjects: 70
Study: 37696652

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Atezolizumab (excluding pseudo-progression)
Number of subjects: 612
Study: 37696667

Group type: EXPERIMENTAL
Intervention: Upacicalcet
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 37696935

Group type: EXPERIMENTAL
Intervention: lefitolimod (TLR9 agonist)/placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: placebo/broadly neutralizing anti-HIV-1 antibodies (bNAbs)
Number of subjects: 43

Group type: COMPARATOR
Intervention: placebo/placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: lefitolimod/bNAb
Number of subjects: 43
Study: 37696968

Group type: EXPERIMENTAL
Intervention: Video-assisted CPR (V-CPR)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Telephone-assisted CPR (T-CPR)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Unassisted CPR (U-CPR)
Number of subjects: 147
Study: 37697121

Group type: EXPERIMENTAL
Intervention: Tapinarof cream 1% once daily
Number of subjects: 0
Study: 37697124

Group type: EXPERIMENTAL
Intervention: EEG features
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: fMRI features
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Independent clinical predictors
Number of subjects: 123
Study: 37697129

Group type: EXPERIMENTAL
Intervention: Structured educational intervention (6-week program with online lectures, instructional videos, educational handouts, and bedside teaching)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Structured educational intervention
Number of subjects: 430
Study: 37697134

Group type: EXPERIMENTAL
Intervention: Sildenafil (PDE-5 inhibitor)
Number of subjects: 160
Study: 37697238

Group type: EXPERIMENTAL
Intervention: Machine learning models using radiomic features from multiparametric MRI for predicting molecular subgroups of PLGGs.
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Machine learning models using radiomic features from multiparametric MRI for predicting KIAA1549-BRAF fusion.
Number of subjects: 61
Study: 37697327

Group type: EXPERIMENTAL
Intervention: e-cigarettes (closed pod system, 3% nicotine salt, tobacco flavour) plus cytisine
Number of subjects: 800

Group type: COMPARATOR
Intervention: e-cigarettes alone
Number of subjects: 800

Group type: COMPARATOR
Intervention: cytisine alone
Number of subjects: 800
Study: 37697331

Group type: EXPERIMENTAL
Intervention: Bifactor model of the IKDC
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: One-factor model of the IKDC
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Two-factor model of the IKDC
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: IKDC questionnaire
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Secondary factors (symptoms, activity level, activities of daily living, sport)
Number of subjects: 606
Study: 37697386

Group type: EXPERIMENTAL
Intervention: Long-span rigid fixed prostheses
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Splitting the full arch prosthesis
Number of subjects: 9
Study: 37697389

Group type: EXPERIMENTAL
Intervention: Compression sleeve
Number of subjects: 15

Group type: COMPARATOR
Intervention: No compression sleeve
Number of subjects: 15
Study: 37697396

Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 52
Study: 37697402

Group type: EXPERIMENTAL
Intervention: Doppler ultrasound diagnosis of TOS
Number of subjects: 82
Study: 37697429

Group type: EXPERIMENTAL
Intervention: Integration of traditional care with modern TB care, including referral linkage, training of health professionals and traditional care providers, and TB screening at traditional health care sites.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 0